9.32
0.00 (0.00%)
| Penutupan Terdahulu | 9.32 |
| Buka | 9.28 |
| Jumlah Dagangan | 17,591 |
| Purata Dagangan (3B) | 95,337 |
| Modal Pasaran | 94,387,368 |
| Harga / Jualan (P/S) | 1.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2025 - 16 May 2025 |
| Margin Keuntungan | -27.54% |
| Margin Operasi (TTM) | 1.58% |
| EPS Cair (TTM) | -2.12 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 12.90% |
| Nisbah Semasa (MRQ) | 0.770 |
| Aliran Tunai Operasi (OCF TTM) | -44.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -34.05 M |
| Pulangan Atas Aset (ROA TTM) | -8.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | OptiNose, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | -1.75 |
|
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.42% |
| % Dimiliki oleh Institusi | 73.90% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mvm Partners, Llc | 31 Dec 2024 | 973,684 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 9.00 (HC Wainwright & Co., -3.43%) | Pegang |
| 9.00 (Piper Sandler, -3.43%) | Pegang | |
| 9.00 (Lake Street, -3.43%) | Pegang | |
| Median | 9.00 (-3.43%) | |
| Purata | 9.00 (-3.43%) | |
| Jumlah | 3 Pegang | |
| Harga Purata @ Panggilan | 6.10 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 May 2025 | 9.00 (-3.43%) | Pegang | 0.000 |
| 21 Mar 2025 | 9.00 (-3.43%) | Pegang | 9.15 | |
| Piper Sandler | 21 Mar 2025 | 9.00 (-3.43%) | Pegang | 9.15 |
| Lake Street | 20 Mar 2025 | 9.00 (-3.43%) | Pegang | 9.15 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 21 May 2025 | Pengumuman | Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies |
| 26 Mar 2025 | Pengumuman | Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights |
| 20 Mar 2025 | Pengumuman | OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals |
| 19 Mar 2025 | Pengumuman | Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call |
| 11 Mar 2025 | Pengumuman | Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |